摘要
目的 评价芳香化酶抑制剂与他莫昔芬治疗Luminal型绝经后乳腺癌的疗效.方法 通过检索1993年1月1日至2013年1月1日PubMED、Science Direct、EBSCO Host、EMbase、The Cochrane Library、中国学术期刊全文数据库、万方数据库、维普中文科技期刊全文数据库,对纳入研究的方法学进行评价.对纳入文献的质量进行严格评价和资料提取,使用Review Manager 5.0软件对符合质量标准的随机临床试验（RCT）行系统评价.结果 12篇RCT共纳入2634例患者,其中治疗组1354例（使用芳香化酶抑制剂）,对照组1280例（使用他莫昔芬）,系统评价结果显示：相比对照组,治疗组可显著提升患者1年的无瘤生存率（RR值为1.10,95％ CI为1.01～1.19）、可显著提升患者3年的无瘤生存率（RR值为1.09,95％ CI为1.05～ 1.13）、可显著提升患者1年的总体有效率（RR值为1.21,95％ CI为1.12～1.30）、可显著降低患者3年的心血管疾患发生率（RR值为0.47,95％ CI为0.27～0.83）,患者3年的骨关节疾患发生率比较差异无统计学意义（RR值为0.99,95％ CI为0.61～ 1.61）.结论 相比于他莫昔芬,芳香化酶抑制剂治疗Luminal型绝经后乳腺癌的疗效显著,值得推广.
Objective To evaluate the efficacy in aromatase inhibitors and tamoxifen on Luminal postmenopausal breast neoplasms.Methods PubMED,Science Direct,EBSCO Host,EMbase,The Cochrane Library,CNKI,CECDB and CQVIP were retrieved,the evaluation methodology included.The quality of the included studies and extracted data should be researched rigorously.Review Manager 5.0 software was used to evaluate the quality standards of randomized clinical trial （RCT）.Results Twelve RCT were selected,included 2634 patients,1354 cases of treatment group （use aromatase inhibitors）,1280cases of control group （use tamoxifen）.The results of the evaluation of the system：compared to control group,treatment group significantly improved disease-free survival in 1 year （RR =1.10,95% CI 1.01-1.19）,disease-free survival in 3 years （RR =1.09,95% CI 1.05-1.13）,the overall efficiency in 1 year （RR =1.21,95% CI 1.12-1.30）,furthermore treatment group significantly reduced the incidence of cardiovascular diseases in 3 years （RR =0.47,95% CI 0.27-0.83）,but there was no significant difference in the incidence of bone and joint disease in 3 years between the 2 groups （RR =0.99,95% CI 0.61-1.61）.Conclusion Compared to tamoxifen,the efficacy of aromatase inhibitors is excellent in treatment of Luminal postmenopausal breast neoplasms,it is worth promoting.
出处
《中国医师进修杂志》
2013年第30期31-38,共8页
Chinese Journal of Postgraduates of Medicine
